Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 24 Carcinoma, Non-Small-Cell Lung 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Pancreatic Neoplasms 5 Neoplasms 5 Lung Neoplasms 5 Leukemia, Myeloid, Acute 5 Triple Negative Breast Neoplasms 4 Melanoma 4 Leukemia, Myelomonocytic, Chronic 4 Carcinoma, Renal Cell 4 Breast Diseases 4 Urinary Bladder Neoplasms 3 Thoracic Neoplasms 3 Respiratory Tract Neoplasms 3 Lymphoma 3 Lung Diseases 3 Leukemia, Myelomonocytic, Acute 3 Kidney Neoplasms 3 Fallopian Tube Neoplasms 3 Congenital Abnormalities 3 Colonic Neoplasms 3 Bronchial Neoplasms 3 Vulvar Neoplasms 2 Vaginal Neoplasms 2 Uveal Melanoma 2 Uterine Cervical Neoplasms 2 Sezary Syndrome 2 Recurrence 2 Rectal Neoplasms 2

Interventions

exemestane 1 entinostat 1 Mammography 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Mammary Neoplasms, Animal × entinostat × Clear all

NCT00676663 2022-05-11

ENCORE301

Syndax Pharmaceuticals

Phase 2 Completed

130 enrolled 18 charts

Breast Neoplasms, Mammary Neoplasms, Animal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡